Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Expert InterviewsAround the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology Brothers
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthInteractive ToolsNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe
Advertisement

Chemo/Immunotherapy Confers Greater Therapy-Related MDS/AML Risk in Survivors

August 3, 2023
By Russ Conroy
News
Article

Investigators note that although therapy-related myelodysplastic syndromes or acute myeloid leukemia are not common, efforts to reduce treatment-associated toxicity in survivors of lymphoid neoplasms are needed given the poor prognosis associated with the diagnosis.

"With further advances in therapeutic approaches for lymphoid neoplasms, future studies with additional follow-up, newer therapies, and detailed clinical data will be important for assessing [therapy-related] MDS/AML risks and informing evolving risk/benefit assessments for specific treatment regimens," according to the study authors.

"With further advances in therapeutic approaches for lymphoid neoplasms, future studies with additional follow-up, newer therapies, and detailed clinical data will be important for assessing [therapy-related] MDS/AML risks and informing evolving risk/benefit assessments for specific treatment regimens," according to the study authors.

Survivors of lymphoid neoplasms who received initial chemotherapy or immunotherapy may have a higher risk of developing therapy-related myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML), although those treated more recently generally had a lower risk, according to findings from a study published in The Lancet.

There were 1496 instances of therapy-related MDS/AML diagnosed during a median follow-up of 3.9 years (interquartile range [IQR], 1.5-8.1). The incidence rate of therapy-related MDS/AML was 6.4 times (95% CI, 6.1-6.7) higher than what was expected in the general population. Moreover, investigators noted an excess absolute risk (EAR) of 12.8 instances per 10,000 person-years.

Investigators observed an elevated risk of therapy-related MDS/AML following initial chemotherapy or immunotherapy for patients with precursor leukemia/lymphoma (standardized incidence ratio [SIR], 39; EAR, 30), Burkitt leukemia/lymphoma (SIR, 20; EAR, 24), peripheral T-cell lymphoma (PTCL; SIR, 12; EAR, 23), and chronic lymphocytic leukemia (CLL) or small lymphocytic leukemia (SLL; SIR, 9.0; EAR, 27). There were also elevated risks after initial treatment for Hodgkin lymphoma, follicular lymphoma, plasma cell neoplasms, diffuse large B-cell lymphoma (DLBCL), and marginal zone lymphoma (MZL; SIRs, 4.2-6.9; EARs, 4.9-15.0).

In an analysis of 10-year cumulative incidence rates of therapy-related MDS/AML, the highest risks were for patients receiving treatment for Burkitt leukemia/lymphoma (2.0%), CLL/SLL (1.9%), mantle cell lymphoma (MCL; 1.7%), precursor leukemia/lymphoma (1.4%), and PTCL (1.4%). Moreover, the median survival following therapy-related MDS/AML was 8.0 months (IQR, 3.0-22.0).

“Despite the rarity of [therapy-related] MDS/AML, the 8-month median survival after [therapy-related] MDS/AML diagnosis emphasizes the high fatality rate of this rare outcome,” the study authors wrote. “With further advances in therapeutic approaches for lymphoid neoplasms, future studies with additional follow-up, newer therapies, and detailed clinical data will be important for assessing [therapy-related] MDS/AML risks and informing evolving risk/benefit assessments for specific treatment regimens.”

Patients who received initial treatment for CLL/SLL experienced a higher risk of therapy-related MDS/AML when treated more recently compared with those receiving treatment earlier in the study period (SIR2000-2005, 4.8; SIR2006-2011, 13; SIR2012-2017, 10; Ptrend = .0043). This risk declined significantly for patients who received more recent treatment for Hodgkin lymphoma (SIR2000-2005, 15; SIR2006-2011, 7.1; SIR2012-2017, 6.3; Ptrend = .024); the same was true for patients with MZL (SIR2000-2005, 7.5; SIR2006-2011, 4.6; SIR2012-2017, 2.3; Ptrend = .015).

Investigators noted lower SIRs for therapy-related MDS/AML risk in the most recent calendar period of 2012 to 2017 for patients with MCL (Ptrend = .054), lymphoblastic lymphoma or Waldenström macroglobulinemia (Ptrend = .067), and plasma cell neoplasms (Ptrend = .051). Additionally, there was no temporal change in risk for therapy-related MDS/AML in patients receiving initial therapy for DLBCL (Ptrend = .025).

The 5-year cumulative incidence of therapy-related MDS/AML increased from 0.49% during 2000 to 2005 to 1.5% during 2006 to 2011 and 1.1% during 2012 to 2017 for patients treated for CLL/SLL. For patients with Hodgkin lymphoma, the 5-year cumulative incidence rate was 0.38% during 2000 to 2005, 0.22% during 2006 to 2011, and 0.20% during 2012 to 2017. For those with MZL, the 5-year rate was 0.71% during 2000 to 2005, 0.47% during 2006 to 2011, and 0.19% during 2012 to 2017.

Investigators of this study assessed data from patients diagnosed with a first primary lymphoid malignancy at ages 20 to 84 from 2000 to 2017 who survived at least 1 year following diagnosis without developing a second malignancy and received initial chemotherapy or immunotherapy. These data came from 17 National Cancer Institute Surveillance, Epidemiology, and End Results cancer registry areas that made up 27.8% of the United States population. Investigators did not include data from patients under the age of 20, as treatment approaches may have differed for pediatric patients.

Investigators quantified the observed or expected relative risk of therapy-related MDS/AML occurrence compared with that expected in the general population using SIRs. Other measures included EARs or the observed/expected risk per 10,000 person-years, cumulative incidence of therapy-related MDS/AML, and median survival following therapy-related MDS/AML.

The study cohort included 186,503 patients who received initial chemotherapy or immunotherapy. At least 67% of those with first primary Hodgkin lymphoma, precursor leukemia/lymphoma, Burkitt leukemia/lymphoma, MCL, DLBCL, hairy cell leukemia, and plasma cell neoplasms received initial treatment. Moreover, less than 35% of those with CLL/SLL and MZL received initial treatment.

Median patient ages at diagnosis ranged from 53.5 to 67.5 years outside of those with Hodgkin lymphoma (37.5 years; IQR, 27.5-51.5), precursor leukemia/lymphoma (40.5 years; IQR, 28.5-54.5), and Burkitt leukemia/lymphoma (45.5 years; IQR, 34.5-57.5). Initial therapy also most commonly included radiotherapy for those with Hodgkin lymphoma (34.3%), precursor leukemia/lymphoma (26.2%), DLBCL (25.8%), and plasma cell neoplasms (22.9%).

Reference

Morton LM, Curtis RE, Linet MS, et al. Trends in risk for therapy-related myelodysplastic syndrome/acute myeloid leukemia after initial chemo/immunotherapy for common and rare lymphoid neoplasms, 2000–2018. EClinicalMedicine. 2023;61:102060 doi:10.1016/j.eclinm.2023.102060

Recent Videos
Acupuncture
Jun J. Mao, MD, MSCE
Next Steps in Evaluating Medicare’s Impact on Cancer Mortality Rates
medication
Medicaid expansion
Acupuncture
Related Content
Advertisement

Bexmarilimab/Chemo Yield Positive Responses in Myelodysplastic Syndromes

Bexmarilimab/Chemo Yield Positive Responses in Myelodysplastic Syndromes

Tim Cortese
April 17th 2025
Article

Topline results from the phase 1/2 BEXMAB trial showed “one of the strongest data sets ever seen” in treatment-resistant higher-risk MDS populations.


Authors of an article published in ONCOLOGY® detail how a novel multidisciplinary lifestyle medicine clinic can meet the needs of cancer survivors.

Using Multidisciplinary Lifestyle Medicine to Enhance Cancer Survivor QOL

Rachel A. Millstein, PhD, MHS;Loren Winters, NP;Amy Comander, MD
January 6th 2025
Podcast

Authors of an article published in ONCOLOGY® detail how a novel multidisciplinary lifestyle medicine clinic can meet the needs of cancer survivors.


Phase 1b data support the potential benefits of R289 as a treatment for patients with lower-risk myelodysplastic syndrome.

Novel IRAK1/4 Inhibitor Receives FDA Orphan Drug Designation in MDS

Russ Conroy
January 12th 2025
Article

Phase 1b data support the potential benefits of R289 as a treatment for patients with lower-risk myelodysplastic syndrome.


Andrew M. Evens, DO, MBA, MSc, discusses the importance of meeting the emotional and physical needs of cancer survivors to help them lead fruitful lives.

Ensuring Holistic, Individualized Transitions of Care for Cancer Survivors

Andrew M. Evens, DO, MBA, MSc
December 9th 2024
Podcast

Andrew M. Evens, DO, MBA, MSc, discusses the importance of meeting the emotional and physical needs of cancer survivors to help them lead fruitful lives.


The venetoclax regimen improved CR/CRi rates for patients with acute myeloid leukemia and myelodysplastic syndromes.

Venetoclax/Cladribine Improves Response Rates in AML/MDS Cohorts

Ariana Pelosci
December 9th 2024
Article

The venetoclax regimen improved CR/CRi rates for patients with acute myeloid leukemia and myelodysplastic syndromes.


Minimal tumor lysis syndrome was observed with venetoclax combined with hypomethylating agents in patients with myelodysplastic syndrome.

Venetoclax Plus Hypomethylating Agents Elicit Encouraging Responses in MDS

Roman Fabbricatore
December 9th 2024
Article

Minimal tumor lysis syndrome was observed with venetoclax combined with hypomethylating agents in patients with myelodysplastic syndrome.

Related Content
Advertisement

Bexmarilimab/Chemo Yield Positive Responses in Myelodysplastic Syndromes

Bexmarilimab/Chemo Yield Positive Responses in Myelodysplastic Syndromes

Tim Cortese
April 17th 2025
Article

Topline results from the phase 1/2 BEXMAB trial showed “one of the strongest data sets ever seen” in treatment-resistant higher-risk MDS populations.


Authors of an article published in ONCOLOGY® detail how a novel multidisciplinary lifestyle medicine clinic can meet the needs of cancer survivors.

Using Multidisciplinary Lifestyle Medicine to Enhance Cancer Survivor QOL

Rachel A. Millstein, PhD, MHS;Loren Winters, NP;Amy Comander, MD
January 6th 2025
Podcast

Authors of an article published in ONCOLOGY® detail how a novel multidisciplinary lifestyle medicine clinic can meet the needs of cancer survivors.


Phase 1b data support the potential benefits of R289 as a treatment for patients with lower-risk myelodysplastic syndrome.

Novel IRAK1/4 Inhibitor Receives FDA Orphan Drug Designation in MDS

Russ Conroy
January 12th 2025
Article

Phase 1b data support the potential benefits of R289 as a treatment for patients with lower-risk myelodysplastic syndrome.


Andrew M. Evens, DO, MBA, MSc, discusses the importance of meeting the emotional and physical needs of cancer survivors to help them lead fruitful lives.

Ensuring Holistic, Individualized Transitions of Care for Cancer Survivors

Andrew M. Evens, DO, MBA, MSc
December 9th 2024
Podcast

Andrew M. Evens, DO, MBA, MSc, discusses the importance of meeting the emotional and physical needs of cancer survivors to help them lead fruitful lives.


The venetoclax regimen improved CR/CRi rates for patients with acute myeloid leukemia and myelodysplastic syndromes.

Venetoclax/Cladribine Improves Response Rates in AML/MDS Cohorts

Ariana Pelosci
December 9th 2024
Article

The venetoclax regimen improved CR/CRi rates for patients with acute myeloid leukemia and myelodysplastic syndromes.


Minimal tumor lysis syndrome was observed with venetoclax combined with hypomethylating agents in patients with myelodysplastic syndrome.

Venetoclax Plus Hypomethylating Agents Elicit Encouraging Responses in MDS

Roman Fabbricatore
December 9th 2024
Article

Minimal tumor lysis syndrome was observed with venetoclax combined with hypomethylating agents in patients with myelodysplastic syndrome.

Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.